Protein Aggregation Detection via Gibbs Energy Concentration Dependence
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Protein aggregation poses a significant challenge to the long-term stability of protein preparations, particularly biologics, due to the presence of denatured or partially denatured proteins that tend to aggregate, especially in antibody drug conjugates, leading to reduced effective doses and unwanted immunological responses.
Innovation Solution
A method is developed to determine and characterize protein aggregation processes by measuring the Gibbs energy of stability (ΔG) at varying protein concentrations, using observable properties such as fluorescence, to identify the amount and fraction of aggregated and denatured proteins, allowing for the selection of protein formulations that minimize aggregation and extend stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If protein formulations are prepared with higher concentrations to improve therapeutic potency, then the effective dose is improved, but protein aggregation increases and stability decreases
Solution Approach 1:
The method performs preliminary assessment of aggregation tendency by measuring ΔG at multiple concentrations before final formulation selection. This allows identification of optimal concentrations that maintain stability while achieving therapeutic potency, preventing aggregation issues before they occur in the final product.
Solution Approach 2:
The invention systematically varies protein concentration as a parameter to establish the relationship between concentration and aggregation tendency. By measuring ΔG at different concentrations (e.g., 0.1, 0.5, 1.0, 5.0 mg/mL), the method identifies the optimal concentration range that balances therapeutic potency with minimal aggregation, resolving the contradiction between quantity and stability.
2Measurement precision
If conventional aggregation detection methods are used, then aggregation can be detected, but only after significant aggregation has occurred, delaying formulation optimization
Solution Approach 1:
The method performs preliminary detection of aggregation tendency by measuring ΔG at early stages and low concentrations. This preliminary assessment predicts future aggregation behavior before significant aggregation occurs, enabling early formulation optimization and preventing time loss in later development stages.
Solution Approach 2:
The invention uses ΔG (Gibbs free energy of folding) as an intermediary parameter to indirectly detect aggregation tendency. Instead of directly measuring aggregates (which requires significant aggregation), the method measures ΔG at multiple concentrations and uses the concentration dependence of ΔG as a predictive intermediary indicator of aggregation propensity, enabling early detection.
3Stability of the object's composition
If multiple protein variants are screened to find stable variants, then aggregation resistance is improved, but the complexity and time of screening increases
Solution Approach 1:
The method uses a universal screening approach based on ΔG concentration dependence that can be applied to any protein variant. This single methodology serves multiple functions: it screens for stability, predicts aggregation tendency, and identifies optimal formulation conditions simultaneously, reducing overall screening complexity while maintaining high stability assessment capability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the rapid determination of protein aggregation, allowing for the identification of protein variants and formulations with maximized stability and minimized aggregation, thereby prolonging the shelf life and therapeutic potency of biologics.
Implementation Method 1
measuring an observable property for each solution in the plurality of first solutions
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to, among other things, methods and systems for recognizing and characterizing protein aggregation processes at the earliest possible time and use of such new methods and systems for (1) the identification and selection of protein formulations that minimize aggregation and extend long-term stability and (2) the identification of protein variants with the lowest tendency to aggregate.